EOM Pharmaceuticals Holdings, Inc.
IMUC · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.66 | 0.41 | 0.58 | -0.09 |
| FCF Yield | -13.79% | -5.41% | -2.83% | -12.09% |
| EV / EBITDA | -21.28 | -30.76 | -43.36 | -20,411,584.48 |
| Quality | ||||
| ROIC | 1,140.12% | 183.43% | 5,609.73% | -217.62% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.42 | 0.88 | 0.99 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -88.44% | 45.79% | -13.74% | -86.45% |
| Safety | ||||
| Net Debt / EBITDA | -0.37 | -4.46 | -1.29 | -1,330,210.00 |
| Interest Coverage | -2.08 | -3.00 | -13.65 | -308.85 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |